

# Vladimir Tolmachev

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5325707/vladimir-tolmachev-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

296  
papers

9,419  
citations

51  
h-index

80  
g-index

313  
ext. papers

10,428  
ext. citations

5.2  
avg, IF

6.11  
L-index

#	Paper	IF	Citations
296	Targeted nuclear medicine. Seek and destroy.. <i>Russian Chemical Reviews</i> , <b>2022</b> , 91,	6.8	3
295	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	1
294	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	2
293	A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers. <i>Applied Materials Today</i> , <b>2021</b> , 25, 101199	6.6	5
292	EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT). <i>Siberian Journal of Oncology</i> , <b>2021</b> , 20, 170-178	0.3	1
291	Preclinical Evaluation of Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
290	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	2
289	Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. <i>Bulletin of Siberian Medicine</i> , <b>2021</b> , 20, 23-30	0.4	4
288	PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	7
287	Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer. <i>Vestnik Rentgenologii I Radiologii</i> , <b>2021</b> , 102, 89-97	0.3	
286	Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody Molecules Lu-ABY-271 and Lu-ABY-027: Impact of DOTA Position on ABD Domain. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	2
285	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
284	Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle. <i>Biomaterials</i> , <b>2021</b> , 266, 120381	15.6	3
283	Phase I Study of Tc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 493-499	8.9	25
282	Single-photon emission computerized tomography with 99mTC-DARPIN9_29 in diagnostics of breast cancer with Her2/neu overexpression: first clinical experience. <i>Molekulyarnaya Meditsina (Molecular Medicine)</i> , <b>2021</b> , 19, 41-46	0.1	
281	Preclinical Evaluation of Tc-Labeled GRPR Antagonists maSSS/SES-PEG-RM26 for Imaging of Prostate Cancer. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	2
280	Comparative Evaluation of Novel Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6

279	Phase I clinical study of a new radiopharmaceutical based on recombinant target molecules DARPin9_29 labeled with technetium-99m for radionuclide diagnosis of the Her2/neu-positive breast cancer. <i>Molekulyarnaya Meditsina (Molecular Medicine)</i> , <b>2021</b> , 19, 41-48	0.1	
278	Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [Ga]Ga-NOTA-PEG-RM26. <i>Scientific Reports</i> , <b>2021</b> , 11, 3631	4.9	4
277	The Use of a Non-Conventional Long-Lived Gallium Radioisotope Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	4
276	The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. <i>Seminars in Cancer Biology</i> , <b>2021</b> , 72, 185-197	12.7	6
275	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
274	Phase I trial of Tc-(HE)-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer. <i>Journal of Nuclear Medicine</i> , <b>2021</b> ,	8.9	9
273	HER3 PET Imaging: Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
272	Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	8
271	Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	4
270	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	8
269	Affibody Molecules as Targeting Vectors for PET Imaging. <i>Cancers</i> , <b>2020</b> , 12,	6.6	32
268	Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
267	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	2
266	Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. <i>EJNMMI Research</i> , <b>2020</b> , 10, 21	3.6	4
265	Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. <i>EJNMMI Radiopharmacy and Chemistry</i> , <b>2020</b> , 5, 16	5.8	19
264	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. <i>Current Medicinal Chemistry</i> , <b>2020</b> , 27, 7090-7111	4.3	5
263	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. <i>Cancers</i> , <b>2020</b> , 13,	6.6	7
262	Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. <i>International Journal of Biological Macromolecules</i> , <b>2020</b> , 145, 216-225	7.9	13

261	Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPIn Ec1. <i>Molecules</i> , <b>2020</b> , 25,	4.8	6
260	Efficient Synthesis of [ <sup>18</sup> F]Fluoroaliphatic Carboxylic Esters and Acids for Positron Emission Tomography. <i>European Journal of Organic Chemistry</i> , <b>2020</b> , 2020, 6375-6381	3.2	1
259	Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. <i>Pharmaceutics</i> , <b>2020</b> , 12,	6.4	7
258	Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting. <i>Scientific Reports</i> , <b>2020</b> , 10, 20777	4.9	6
257	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. <i>Molecules</i> , <b>2020</b> , 25,	4.8	2
256	Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting. <i>Methods in Molecular Biology</i> , <b>2020</b> , 2105, 283-304	1.4	3
255	Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	13
254	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. <i>Scientific Reports</i> , <b>2019</b> , 9, 655	4.9	13
253	Indirect Radioiodination of DARPIn G3 Using N-succinimidyl-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	12
252	Selection of the optimal macrocyclic chelators for labeling with In and Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2019</b> , 140, 109-120	5.7	12
251	Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist Lu-DOTAGA-PEG -RM26. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3347-3358	7.5	14
250	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. <i>Scientific Reports</i> , <b>2019</b> , 9, 6779	4.9	6
249	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. <i>Biomaterials</i> , <b>2019</b> , 203, 73-85	15.6	13
248	Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPIn) G3 variants for molecular imaging of HER2. <i>International Journal of Oncology</i> , <b>2019</b> , 54, 1209-1220	4.4	9
247	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of Ga-Labeled Tracers. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	15
246	Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart. <i>Pharmaceutics</i> , <b>2019</b> , 11,	6.4	5
245	Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. <i>Cancers</i> , <b>2019</b> , 11,	6.6	6
244	Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. <i>Pharmaceutics</i> , <b>2019</b> , 11,	6.4	11

243	Optimal composition and position of histidine-containing tags improves biodistribution of Tc-labeled DARPIn G3. <i>Scientific Reports</i> , <b>2019</b> , 9, 9405	4.9	23
242	Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A. <i>International Journal of Oncology</i> , <b>2019</b> , 55, 309-319	4.4	7
241	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. <i>Scientific Reports</i> , <b>2019</b> , 9, 17086	4.9	10
240	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. <i>Scientific Reports</i> , <b>2019</b> , 9, 14907	4.9	9
239	Increase in negative charge of Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. <i>Scientific Reports</i> , <b>2019</b> , 9, 17710	4.9	10
238	CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models. <i>Scientific Reports</i> , <b>2019</b> , 9, 18898	4.9	13
237	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2019</b> , 134, 37-48	5.7	15
236	Comparative Evaluation of Two DARPIn Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. <i>Molecular Pharmaceutics</i> , <b>2019</b> , 16, 995-1008	5.6	23
235	Basic and practical concepts of radiopharmaceutical purification methods. <i>Drug Discovery Today</i> , <b>2019</b> , 24, 315-324	8.8	5
234	Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-ZEGFR:2377. <i>Oncology Reports</i> , <b>2019</b> , 41, 534-542	3.5	3
233	Enhanced protection of the renal vascular endothelium improves early outcome in kidney transplantation: Preclinical investigations in pig and mouse. <i>Scientific Reports</i> , <b>2018</b> , 8, 5220	4.9	17
232	Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe. <i>Scientific Reports</i> , <b>2018</b> , 8, 2998	4.9	15
231	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 1092-1098	8.9	33
230	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of Tc-labeled anti-EGFR affibody molecules. <i>Amino Acids</i> , <b>2018</b> , 50, 981-994	3.5	11
229	Molecular design of radiocopper-labelled Affibody molecules. <i>Scientific Reports</i> , <b>2018</b> , 8, 6542	4.9	10
228	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 885-891	8.9	71
227	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 93-99	8.9	28
226	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPIn 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. <i>Contrast Media and Molecular Imaging</i> , <b>2018</b> , 2018, 6930425	3.2	24

225	Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. <i>Molecular Pharmaceutics</i> , <b>2018</b> , 15, 3394-3403	5.6	15
224	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with In and Ga. <i>Molecular Pharmaceutics</i> , <b>2018</b> , 15, 2674-2683	5.6	12
223	Cyclic versus Noncyclic Chelating Scaffold for Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. <i>Molecular Pharmaceutics</i> , <b>2018</b> , 15, 175-185	5.6	24
222	Preclinical Evaluation of [Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. <i>Cells</i> , <b>2018</b> , 7,	7.9	13
221	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. <i>Theranostics</i> , <b>2018</b> , 8, 4462-4476	12.1	19
220	Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. <i>Cells</i> , <b>2018</b> , 7,	7.9	14
219	Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. <i>Journal of Controlled Release</i> , <b>2018</b> , 288, 84-95	11.7	29
218	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. <i>Scientific Reports</i> , <b>2018</b> , 8, 9643	4.9	8
217	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. <i>Scientific Reports</i> , <b>2017</b> , 7, 43118	4.9	16
216	Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 1337-1346	8.8	29
215	Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with Cu Using NOTA and NODAGA. <i>Contrast Media and Molecular Imaging</i> , <b>2017</b> , 2017, 8565802	3.2	10
214	High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. <i>Contrast Media and Molecular Imaging</i> , <b>2017</b> , 2017, 6873684	3.2	21
213	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. <i>International Journal of Oncology</i> , <b>2017</b> , 51, 1765-1774	4.4	10
212	The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule. <i>Scientific Reports</i> , <b>2017</b> , 7, 5961	4.9	27
211	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. <i>Scientific Reports</i> , <b>2017</b> , 7, 14780	4.9	13
210	Pretargeted Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1553-1559	8.9	96
209	Evaluation of the first Sc-labeled Affibody molecule for imaging of HER2-expressing tumors. <i>Nuclear Medicine and Biology</i> , <b>2017</b> , 45, 15-21	2.1	22
208	Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin. <i>International Journal of Oncology</i> , <b>2016</b> , 49, 1185-94	4.4	21

207	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. <i>Molecular Pharmaceutics</i> , <b>2016</b> , 13, 3676-3687	5.6	24
206	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with <sup>99m</sup> Tc using a peptide-based cysteine-containing chelator. <i>International Journal of Oncology</i> , <b>2016</b> , 49, 2285-2293	4.4	21
205	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6. <i>Bioconjugate Chemistry</i> , <b>2016</b> , 27, 2678-2688	6.3	12
204	Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins. <i>Bioconjugate Chemistry</i> , <b>2016</b> , 27, 716-26	6.3	31
203	Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 431-6	8.9	44
202	Control of growth factor binding and release in bisphosphonate functionalized hydrogels guides rapid differentiation of precursor cells in vitro. <i>Biomaterials Science</i> , <b>2016</b> , 4, 250-4	7.4	12
201	Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. <i>International Journal of Oncology</i> , <b>2016</b> , 48, 2124-34	4.4	20
200	Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. <i>Molecular Pharmaceutics</i> , <b>2016</b> , 13, 1668-78	5.6	28
199	Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors. <i>Theranostics</i> , <b>2016</b> , 6, 93-103	12.1	46
198	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [ <sup>68</sup> Ga]ABY-025 Affibody PET/CT. <i>Theranostics</i> , <b>2016</b> , 6, 262-71	12.1	146
197	Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma. <i>International Journal of Oncology</i> , <b>2016</b> , 48, 461-70	4.4	10
196	VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread. <i>Nature Communications</i> , <b>2016</b> , 7, 11017	17.4	77
195	Novel chemoselective ( <sup>18</sup> F)-radiolabeling of thiol-containing biomolecules under mild aqueous conditions. <i>Chemical Communications</i> , <b>2016</b> , 52, 6083-6	5.8	31
194	PET imaging of epidermal growth factor receptor expression in tumours using <sup>89</sup> Zr-labelled ZEGFR:2377 affibody molecules. <i>International Journal of Oncology</i> , <b>2016</b> , 48, 1325-32	4.4	41
193	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule <sup>68</sup> Ga-ABY-025 in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 867-71	8.9	69
192	Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting. <i>Bioconjugate Chemistry</i> , <b>2015</b> , 26, 1724-36	6.3	28
191	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. <i>Cancer Research</i> , <b>2015</b> , 75, 4364-71	10.1	47
190	Imaging of CAIX-expressing xenografts in vivo using <sup>99m</sup> Tc-HEHEHE-ZCAIX:1 affibody molecule. <i>International Journal of Oncology</i> , <b>2015</b> , 46, 513-20	4.4	24

189	Affibody-mediated PET imaging of HER3 expression in malignant tumours. <i>Scientific Reports</i> , <b>2015</b> , 5, 15226	4.9	51
188	Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity. <i>ChemistryOpen</i> , <b>2015</b> , 4, 174-82	2.3	10
187	Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain. <i>International Journal of Oncology</i> , <b>2015</b> , 47, 601-9	4.4	19
186	Comparative evaluation of <sup>111</sup> In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. <i>Oncology Reports</i> , <b>2015</b> , 34, 1042-8	3.5	25
185	Evaluation of <sup>99m</sup> Tc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. <i>Amino Acids</i> , <b>2015</b> , 47, 303-15	3.5	19
184	The effect of macrocyclic chelators on the targeting properties of the <sup>68</sup> Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26. <i>Nuclear Medicine and Biology</i> , <b>2015</b> , 42, 446-454	2.1	40
183	Non-invasive determination of HER2-expression in metastatic breast cancer by using <sup>68</sup> Ga-ABY025 PET/CT.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 11067-11067	2.2	
182	Methods for radiolabelling of monoclonal antibodies. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1060, 309-30	1.4	26
181	Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde. <i>Bioconjugate Chemistry</i> , <b>2014</b> , 25, 82-92	6.3	24
180	First-in-human molecular imaging of HER2 expression in breast cancer metastases using the <sup>111</sup> In-ABY-025 affibody molecule. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 730-5	8.9	162
179	Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 80-90	12.5	55
178	Gallium-68-labeled affibody molecule for PET imaging of PDGFR $\alpha$ expression in vivo. <i>Molecular Pharmaceutics</i> , <b>2014</b> , 11, 3957-64	5.6	34
177	Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re. <i>European Journal of Medicinal Chemistry</i> , <b>2014</b> , 87, 519-28	6.8	13
176	Imaging of HER3-expressing xenografts in mice using a ( <sup>99m</sup> Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 41, 1450-9	8.8	38
175	Imaging of platelet-derived growth factor receptor $\alpha$ expression in glioblastoma xenografts using affibody molecule <sup>111</sup> In-DOTA-Z09591. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 294-300	8.9	40
174	Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of <sup>68</sup> Ga- compared to <sup>111</sup> In-labeled conjugates. <i>Molecular Imaging</i> , <b>2014</b> , 13,	3.7	11
173	The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a <sup>68</sup> Ga-labeled NOTA-conjugated antagonistic analog of bombesin. <i>Molecules</i> , <b>2014</b> , 19, 10455-72	4.8	46
172	Development of a <sup>124</sup> I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. <i>International Journal of Oncology</i> , <b>2014</b> , 44, 1998-2008	4.4	13



171	188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1842-8	8.9	20
170	Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes. <i>PLoS ONE</i> , <b>2014</b> , 9, e107483	3.7	14
169	Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 2275-92	3.3	13
168	Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 961-8	8.9	69
167	Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging. <i>Nuclear Medicine and Biology</i> , <b>2013</b> , 40, 378-86	2.1	12
166	[ <sup>99m</sup> Tc(CO) <sub>3</sub> ] <sup>+</sup> -(HE) <sub>3</sub> -ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 439-49	8.8	31
165	HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [ <sup>99m</sup> Tc(CO) <sub>3</sub> ] <sup>+</sup> -labeled affibody molecules. <i>Journal of Medicinal Chemistry</i> , <b>2013</b> , 56, 4966-74	8.3	47
164	Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with <sup>68</sup> Ga and <sup>111</sup> In via maleimido derivatives of DOTA and NODAGA. <i>Bioconjugate Chemistry</i> , <b>2013</b> , 24, 1102-9	6.3	37
163	Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging. <i>Bioconjugate Chemistry</i> , <b>2013</b> , 24, 1144-53	6.3	56
162	Specific uptake of an amyloid- $\beta$ protofibril-binding antibody-tracer in APP transgenic mouse brain. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 37, 29-40	4.3	43
161	Influence of macrocyclic chelators on the targeting properties of ( <sup>68</sup> Ga)-labeled synthetic affibody molecules: comparison with ( <sup>111</sup> In)-labeled counterparts. <i>PLoS ONE</i> , <b>2013</b> , 8, e70028	3.7	44
160	In vitro and in vivo evaluation of a ( <sup>18</sup> F)-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging. <i>PLoS ONE</i> , <b>2013</b> , 8, e81932	3.7	40
159	Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. <i>PLoS ONE</i> , <b>2013</b> , 8, e62791	3.7	51
158	Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with <sup>111</sup> In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 481-92	8.8	35
157	Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 953-60	8.9	61
156	Influence of DOTA chelator position on biodistribution and targeting properties of ( <sup>111</sup> In)-labeled synthetic anti-HER2 affibody molecules. <i>Bioconjugate Chemistry</i> , <b>2012</b> , 23, 1661-70	6.3	30
155	Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with <sup>111</sup> In using a maleimido derivative of NODAGA. <i>Nuclear Medicine and Biology</i> , <b>2012</b> , 39, 518-29	2.1	12
154	Engineering of affibody molecules for therapy and diagnostics. <i>Methods in Molecular Biology</i> , <b>2012</b> , 899, 103-26	1.4	67

153	Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2012</b> , 27, 243-51	3.9	10
152	Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. <i>Drug Discovery Today</i> , <b>2012</b> , 17, 1224-32	8.8	55
151	Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. <i>Tumor Biology</i> , <b>2012</b> , 33, 641-51	2.9	17
150	Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 693-702	8.8	9
149	Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules. <i>Amino Acids</i> , <b>2012</b> , 42, 1975-85	3.5	14
148	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. <i>International Journal of Oncology</i> , <b>2012</b> , 40, 1677-82	4.4	17
147	Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 146-53	8.9	58
146	Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 90-7	8.9	41
145	Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I. <i>Journal of Medicinal Chemistry</i> , <b>2011</b> , 54, 3817-26	8.3	43
144	Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand. <i>Protein Expression and Purification</i> , <b>2011</b> , 76, 127-35	2	28
143	Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas. <i>Nuclear Medicine and Biology</i> , <b>2011</b> , 38, 103-12	2.1	12
142	Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate. <i>Nuclear Medicine and Biology</i> , <b>2011</b> , 38, 697-706	2.1	8
141	Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. <i>Nuclear Medicine and Biology</i> , <b>2011</b> , 38, 1093-102	2.1	26
140	Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A?DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. <i>Experimental and Therapeutic Medicine</i> , <b>2011</b> , 2, 523-528	2.1	21
139	Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab. <i>International Journal of Oncology</i> , <b>2011</b> , 38, 1137-43	4.4	11
138	Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2011</b> , 26, 593-601	3.9	6
137	Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2011</b> , 38, 531-9	8.8	42
136	Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 5234-41	5.4	129

135	Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules. <i>Bioconjugate Chemistry</i> , <b>2011</b> , 22, 894-902	6.3	25
134	125I-labeled quercetin as a novel DNA-targeted radiotracer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2011</b> , 26, 469-75	3.9	5
133	Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 461-9	8.9	68
132	Radiobromine-labelled tracers for positron emission tomography: possibilities and pitfalls. <i>Current Radiopharmaceuticals</i> , <b>2011</b> , 4, 76-89	1.8	11
131	Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 892-7	8.9	233
130	Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. <i>Human Antibodies</i> , <b>2010</b> , 19, 107-11	1.3	10
129	Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. <i>Current Medicinal Chemistry</i> , <b>2010</b> , 17, 2636-55	4.3	59
128	HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with $^{111}\text{In}(\text{CO})\text{I}^+$ , and shows improved biodistribution with reduced hepatic radioactivity accumulation. <i>Bioconjugate Chemistry</i> , <b>2010</b> , 21, 2013-22	6.3	63
127	Design of an optimized scaffold for affibody molecules. <i>Journal of Molecular Biology</i> , <b>2010</b> , 398, 232-47	6.5	116
126	Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>2010</b> , 1800, 487-510	4	71
125	Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. <i>Nuclear Medicine and Biology</i> , <b>2010</b> , 37, 539-46	2.1	25
124	Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 992-1000	21.7	88
123	Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1131-8	8.9	73
122	The use of closo-dodecaborate-containing linker improves targeting of HNSCC xenografts with radioiodinated chimeric monoclonal antibody U36. <i>Molecular Medicine Reports</i> , <b>2010</b> , 3, 155-60	2.9	
121	Radionuclide molecular imaging using Affibody molecules. <i>Current Pharmaceutical Biotechnology</i> , <b>2010</b> , 11, 581-9	2.6	49
120	(186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 260-9	8.8	37
119	Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 613-22	8.8	97
118	A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 1356-67	8.8	71

117	Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. <i>FEBS Letters</i> , <b>2010</b> , 584, 2670-80	3.8	439
116	Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50, 274-83	8.9	91
115	Reply: Molecular Imaging of EGFR: It's Time to Go Beyond Receptor Expression <b>2009</b> , 50, 1196-1196		2
114	Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody. <i>Biopolymers</i> , <b>2009</b> , 92, 116-23	2.2	14
113	Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 692-701	8.8	47
112	The influence of Bz-DOTA and CHX-A@DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 1460-8	8.8	26
111	Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 1864-73	8.8	40
110	Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2009</b> , 19, 3912-4	2.9	16
109	On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50, 417-25	8.9	124
108	Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50, 781-9	8.9	90
107	Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. <i>Journal of Molecular Biology</i> , <b>2008</b> , 376, 1388-402	6.5	118
106	Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. <i>Bioconjugate Chemistry</i> , <b>2008</b> , 19, 2568-76	6.3	41
105	Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. <i>Bioconjugate Chemistry</i> , <b>2008</b> , 19, 235-43	6.3	76
104	Evaluation of a maleimido derivative of CHX-A@DTPA for site-specific labeling of affibody molecules. <i>Bioconjugate Chemistry</i> , <b>2008</b> , 19, 1579-87	6.3	23
103	Influence of cell proportions and proliferation rates on FDG uptake in squamous-cell esophageal carcinoma: a PET study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2008</b> , 23, 172-80	3.9	10
102	Imaging of HER-2 overexpression in tumors for guiding therapy. <i>Current Pharmaceutical Design</i> , <b>2008</b> , 14, 2999-3019	3.3	102
101	Differences in radiosensitivity between three HER2 overexpressing cell lines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2008</b> , 35, 1179-91	8.8	14
100	Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2008</b> , 35, 2245-55	8.8	58

99	Choice of Radionuclides and Radiolabelling Techniques <b>2008</b> , 145-174		7
98	( <sup>99m</sup> Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. <i>Bioconjugate Chemistry</i> , <b>2007</b> , 18, 1956-64	6.3	88
97	Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma. <i>Laryngoscope</i> , <b>2007</b> , 117, 1013-8	3.6	10
96	Update: affibody molecules for molecular imaging and therapy for cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2007</b> , 22, 573-84	3.9	50
95	Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , <b>2007</b> , 7, 555-68	5.4	106
94	Biodistribution of <sup>211</sup> At labeled HER-2 binding affibody molecules in mice. <i>Oncology Reports</i> , <b>2007</b> ,	3.5	5
93	Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the <sup>99m</sup> Tc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2007</b> , 34, 722-733	8.8	76
92	<sup>99m</sup> Tc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2007</b> , 34, 1843-53	8.8	69
91	[ <sup>177</sup> Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. <i>Cancer Research</i> , <b>2007</b> , 67, 326-31	10.1	44
90	Biodistribution of <sup>211</sup> At-labeled humanized monoclonal antibody A33. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2007</b> , 22, 480-7	3.9	10
89	Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. <i>Cancer Research</i> , <b>2007</b> , 67, 2178-86	10.1	161
88	Labelling chemistry and characterization of [ <sup>90</sup> Y/ <sup>177</sup> Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. <i>International Journal of Molecular Medicine</i> , <b>2007</b> , 19, 285	4.4	3
87	In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2007</b> , 22, 585-96	3.9	3
86	Radionuclide therapy of HER2-positive microxenografts using a <sup>177</sup> Lu-labeled HER2-specific Affibody molecule. <i>Cancer Research</i> , <b>2007</b> , 67, 2773-82	10.1	179
85	Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay. <i>Tumor Biology</i> , <b>2007</b> , 28, 253-63	2.9	13
84	In vivo evaluation of cysteine-based chelators for attachment of <sup>99m</sup> Tc to tumor-targeting Affibody molecules. <i>Bioconjugate Chemistry</i> , <b>2007</b> , 18, 549-58	6.3	51
83	Labelling chemistry and characterization of [ <sup>90</sup> Y/ <sup>177</sup> Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. <i>International Journal of Molecular Medicine</i> , <b>2007</b> , 19, 285-91	4.4	25
82	Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. <i>International Journal of Molecular Medicine</i> , <b>2007</b> , 19, 485-93	4.4	7

81	Biodistribution of <sup>211</sup> At labeled HER-2 binding affibody molecules in mice. <i>Oncology Reports</i> , <b>2007</b> , 17, 1141-7	3.5	23
80	Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. <i>Current Opinion in Drug Discovery &amp; Development</i> , <b>2007</b> , 10, 167-75		52
79	Pre-clinical evaluation of [ <sup>111</sup> In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. <i>International Journal of Molecular Medicine</i> , <b>2007</b> , 20, 397-404	4.4	20
78	Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2006</b> , 33, 631-8	8.8	58
77	Tumor imaging using a picomolar affinity HER2 binding affibody molecule. <i>Cancer Research</i> , <b>2006</b> , 66, 4339-48	10.1	405
76	In vitro and in vivo characterization of <sup>177</sup> Lu-huA33: a radioimmunoconjugate against colorectal cancer. <i>Nuclear Medicine and Biology</i> , <b>2006</b> , 33, 991-8	2.1	19
75	Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression. <i>Journal of Neuro-Oncology</i> , <b>2006</b> , 77, 33-45	4.8	16
74	Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. <i>Journal of Nuclear Medicine</i> , <b>2006</b> , 47, 512-9	8.9	63
73	Radio-iodination of monoclonal antibody using potassium [ <sup>125</sup> I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI). <i>Anticancer Research</i> , <b>2006</b> , 26, 1217-23	2.3	9
72	<sup>111</sup> In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. <i>Journal of Nuclear Medicine</i> , <b>2006</b> , 47, 846-53	8.9	72
71	An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay <b>2005</b> , 27, 1355		
70	In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2005</b> , 20, 239-48	3.9	75
69	Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. <i>Nuclear Medicine and Biology</i> , <b>2005</b> , 32, 613-22	2.1	21
68	Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives. <i>Carbohydrate Research</i> , <b>2005</b> , 340, 15-24	2.9	18
67	Radiobromination of closo-carboranes using palladium-catalyzed halogen exchange. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2005</b> , 48, 195-202	1.9	11
66	Synthesis and radioiodination of some 9-aminoacridine derivatives for potential use in radionuclide therapy. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2005</b> , 48, 855-871	1.9	8
65	In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2005</b> , 32, 1296-304	8.8	18
64	[ <sup>177</sup> Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2005</b> , 32, 1457-62	8.8	52

63	Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. <i>Bioconjugate Chemistry</i> , <b>2005</b> , 16, 1547-55	6.3	47
62	In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2005</b> , 20, 514-23	3.9	9
61	[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. <i>Oncology Reports</i> , <b>2005</b> , 13, 1169-75	3.5	10
60	Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. <i>Journal of Nuclear Medicine</i> , <b>2005</b> , 46, 1881-8	8.9	88
59	Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT. <i>Physics in Medicine and Biology</i> , <b>2004</b> , 49, 5419-32	3.8	8
58	Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. <i>Acta Oto-Laryngologica</i> , <b>2004</b> , 124, 1078-85	1.6	5
57	Selection and characterization of HER2/neu-binding affibody ligands. <i>Protein Engineering, Design and Selection</i> , <b>2004</b> , 17, 455-62	1.9	144
56	[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2004</b> , 19, 195-204	3.9	10
55	Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2004</b> , 19, 491-501	3.9	11
54	Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB11H11. Aspects of labelling chemistry in aqueous solution using Chloramine-T. <i>Radiochimica Acta</i> , <b>2004</b> , 92, 311-315	1.9	2
53	A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides. <i>Acta Oncologica</i> , <b>2004</b> , 43, 264-75	3.2	24
52	Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , <b>2004</b> , 260, 295-299	1.5	5
51	Preparation, radioiodination and in vitro evaluation of a nido-carborane-dextran conjugate, a potential residualizing label for tumor targeting proteins and peptides. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , <b>2004</b> , 261, 107-112	1.5	7
50	Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives. <i>European Journal of Organic Chemistry</i> , <b>2004</b> , 2004, 3719-3725	3.2	5
49	Synthesis and radioiodination of 7-(3?-ammoniopropyl)-7,8-dicarba-nido-undecaborate(-1), (ANC). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2004</b> , 47, 557-569	1.9	13
48	Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI). <i>Nuclear Medicine and Biology</i> , <b>2004</b> , 31, 205-11	2.1	36
47	Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion. <i>Nuclear Medicine and Biology</i> , <b>2004</b> , 31, 425-33	2.1	46
46	Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in Normal Mice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2004</b> , 19, 491-501	3.9	13

45	Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells. <i>Anticancer Research</i> , <b>2004</b> , 24, 4035-41	2.3	7
44	Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. <i>Current Medicinal Chemistry</i> , <b>2003</b> , 10, 2447-60	4.3	37
43	Feasibility of isotopic exchange in the system [125I] iodide - undecahydro-iodo-closo-dodecaborate(2-) anion. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , <b>2003</b> , 256, 67-71	1.5	5
42	Direct astatination of a tumour-binding protein, human epidermal growth factor, using nido-carborane as a prosthetic group. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , <b>2003</b> , 256, 191-197	1.5	20
41	Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2003</b> , 30, 727-9	8.8	12
40	Combined effect of gefitinib (Iressa/ZD1839) and targeted radiotherapy with 211At-EGF. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2003</b> , 30, 1348-56	8.8	23
39	Feasibility of palladium-catalyzed isotopic exchange between sodium [125I]I and 2-iodo-para-carborane. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2003</b> , 46, 623-631	1.9	11
38	High yield [125I]iodide-labeling of iodinated carboranes by palladium-catalyzed isotopic exchange. <i>Journal of Organometallic Chemistry</i> , <b>2003</b> , 680, 188-192	2.3	26
37	Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. <i>British Journal of Haematology</i> , <b>2003</b> , 120, 853-9	4.5	50
36	Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. Comparison with other radioiodination methods. <i>Bioconjugate Chemistry</i> , <b>2003</b> , 14, 805-10	6.3	16
35	[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2003</b> , 18, 643-54	3.9	15
34	Targeting peptides and positron emission tomography. <i>Biopolymers</i> , <b>2002</b> , 66, 381-92	2.2	38
33	Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma localizing agent. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , <b>2002</b> , 251, 409-412	1.5	2
32	Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2002</b> , 17, 385-96	3.9	12
31	Radiobromination of closo-dodecaborate anion. Aspects of labelling chemistry in aqueous solution using Chloramine-T. <i>Radiochimica Acta</i> , <b>2002</b> , 90, 229-235	1.9	30
30	Polyhedral Boron Compounds as Potential Linkers for Attachment of Radiohalogens to Targeting Proteins and Peptides. A Review. <i>Collection of Czechoslovak Chemical Communications</i> , <b>2002</b> , 67, 913-935		41
29	Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy. <i>Physics in Medicine and Biology</i> , <b>2002</b> , 47, 615-29	3.8	14
28	Elimination of stabilised hyaluronan from the knee joint in healthy men. <i>Clinical Pharmacokinetics</i> , <b>2002</b> , 41, 603-13	6.2	46



27	110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET. <i>Journal of Nuclear Medicine</i> , <b>2002</b> , 43, 1391-7	8.9	32
26	Separation of arsenic from germanium oxide targets by dry distillation. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , <b>2001</b> , 247, 61-66	1.5	14
25	Separation of two labeled components of [111In]-OctreoScan by HPLC. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , <b>2001</b> , 247, 95-99	1.5	1
24	Closo-dodecaborate (2-) anion as a potential prosthetic group for attachment of astatine to proteins. Aspects of the labelling chemistry with chloramine-T. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2000</b> , 43, 251-260	1.9	15
23	Optimization of Iodination of [125I]-N-Succinimidyl-Para-Iodobenzoate Using Chloramine-T for Labeling of Proteins. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , <b>2000</b> , 246, 207-213	1.5	3
22	Positron emission tomography of experimental melanoma with. <i>Nuclear Medicine and Biology</i> , <b>2000</b> , 27, 845-9	2.1	2
21	Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. <i>Nuclear Medicine and Biology</i> , <b>2000</b> , 27, 827-35	2.1	34
20	Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET. <i>Nuclear Medicine and Biology</i> , <b>2000</b> , 27, 837-43	2.1	22
19	114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide. <i>Nuclear Medicine and Biology</i> , <b>2000</b> , 27, 183-8	2.1	26
18	Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetry. <i>Acta Oncologica</i> , <b>1999</b> , 38, 343-9	3.2	16
17	Positron emission tomography and radioimmunotargeting--general aspects. <i>Acta Oncologica</i> , <b>1999</b> , 38, 335-41	3.2	22
16	Kinetics of 76Br-labeled anti-CEA antibodies in pigs; aspects of dosimetry and PET imaging properties. <i>Medical Physics</i> , <b>1999</b> , 26, 249-58	4.4	15
15	Quantification aspects of patient studies with 52Fe in positron emission tomography. <i>Applied Radiation and Isotopes</i> , <b>1999</b> , 51, 707-15	1.7	9
14	Kinetic analysis of 52Fe-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography. <i>British Journal of Haematology</i> , <b>1999</b> , 104, 288-95	4.5	25
13	Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. <i>British Journal of Haematology</i> , <b>1999</b> , 104, 296-302	4.5	57
12	Conjugate chemistry and cellular processing of EGF-dextran. <i>Acta Oncologica</i> , <b>1999</b> , 38, 313-21	3.2	18
11	High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T. <i>Nuclear Medicine and Biology</i> , <b>1999</b> , 26, 923-9	2.1	28
10	Binding of tellurium to hepatocellular selenoproteins during incubation with inorganic tellurite: consequences for the activity of selenium-dependent glutathione peroxidase. <i>International Journal of Biochemistry and Cell Biology</i> , <b>1999</b> , 31, 291-301	5.6	48

9	Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution. <i>Bioconjugate Chemistry</i> , <b>1999</b> , 10, 338-45	6.3	29
8	Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF. <i>Bioconjugate Chemistry</i> , <b>1999</b> , 10, 938-46	6.3	14
7	Synthesis of N-Succinimidyl 4-[76Br]Bromobenzoate and its Use in Conjugation Labelling of Macromolecules.. <i>Acta Chemica Scandinavica</i> , <b>1999</b> , 53, 508-512		17
6	Production of 61Cu from a natural nickel target. <i>Applied Radiation and Isotopes</i> , <b>1998</b> , 49, 79-81	1.7	18
5	Production of 76Br by a low-energy cyclotron. <i>Applied Radiation and Isotopes</i> , <b>1998</b> , 49, 1537-1540	1.7	66
4	Diffusion-based separation methods: Dry distillation of zinc, cadmium and mercury isotopes from irradiated targets. <i>Applied Radiation and Isotopes</i> , <b>1997</b> , 48, 565-569	1.7	3
3	Rapid separation of gallium from zinc targets by thermal diffusion. <i>Applied Radiation and Isotopes</i> , <b>1996</b> , 47, 297-299	1.7	22
2	Rapid separation of 110In from enriched Cd targets by thermal diffusion. <i>Applied Radiation and Isotopes</i> , <b>1995</b> , 46, 859-863	1.7	14
1	Pre-clinical evaluation of [111In]-benzyl-DOTA-ZHER2:342, a potential agent for imaging of HER2 expression in malignant tumors. <i>International Journal of Molecular Medicine</i> ,	4.4	2